<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2064">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134298</url>
  </required_header>
  <id_info>
    <org_study_id>K 2018-6443</org_study_id>
    <nct_id>NCT05134298</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Piperacillin and Meropenem in ICU Patients</brief_title>
  <official_title>First Dose Pharmacokinetics for Piperacillin and Meropenem in ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize the pharmacokinetics of meropenem and&#xD;
      piperacillin in ICU-patients at the time of the first dose administration and to contrast&#xD;
      that with the same measurements obtained in the same patient 2-3 days later during the course&#xD;
      of ICU treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>For the first antibiotic administration and if possible for a second administration 48-72 hour later.</time_frame>
    <description>Apparent volume of distribution calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma clearance</measure>
    <time_frame>For the first antibiotic administration and if possible for a second administration 48-72 hour later.</time_frame>
    <description>Plasma clearance calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma antibiotic concentrations at mid and end of dosing interval</measure>
    <time_frame>For the first antibiotic administration and if possible for a second administration 48-72 hour later.</time_frame>
    <description>Plasma antibiotic concentrations at mid and end of dosing interval</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Antibiotic Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Study Kohort</arm_group_label>
    <description>As specified by study population, inclusion and exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam, Meropenem</intervention_name>
    <description>This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.</description>
    <arm_group_label>Study Kohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ICU-patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patient being treated in one of the participating ICUs and planned to recieve treatment&#xD;
        with meropenem or piperacillin.&#xD;
&#xD;
        Exclusion Criteria (fullfilling any exlusion criteria means that patient cannot be included&#xD;
        in the study):&#xD;
&#xD;
          -  Not possible to retrospectively ask the patient or next of kin for consent to take&#xD;
             part in the study or patient or next-of-kin not providing consent.&#xD;
&#xD;
          -  Not posisble to obtain and process blood samples as specified by protocol.&#xD;
&#xD;
          -  Ongoing renal replacement therapy.&#xD;
&#xD;
          -  Patient having received the same antibiotic within the previous 96 h.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Johan Petersson, MD, Ass Prof</last_name>
    <phone>+46-8-51770000</phone>
    <email>johan.petersson@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Eliasson, MD, Prof</last_name>
    <phone>+46-8-51770000</phone>
    <email>erik.eliasson@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Petersson, MD</last_name>
      <email>johan.petersson@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Johan Petersson</investigator_full_name>
    <investigator_title>Senior ICU consultant, Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

